Monitor the final IPO pricing and the Nasdaq listing approval. The concurrent Sanofi private placement provides a strategic endorsement. Key catalysts are the Phase 2 primary results for WIN378 in asthma (1H 2027) and full Phase 1 results for WIN027 (1H 2027).
Executive Summary
Windward Bio Group AG, a Swiss clinical-stage biotech, filed Amendment No. 2 to its F-1 registration statement for an IPO of 10,294,117 common shares on Nasdaq (symbol WWB) at an estimated price range of $16.00-$18.00 per share. The filing also discloses a concurrent $50 million private placement with Sanofi for common shares and pre-funded warrants. The company is developing ultra-long-acting antibody therapies for respiratory and dermatologic diseases, with lead candidates WIN378 (anti-TSLP) and WIN027 (anti-TSLP/IL-13 bispecific).
Key Financial Metrics
Key Facts
- IPO of 10,294,117 common shares at estimated $16.00-$18.00 per share on Nasdaq under symbol WWB.
- Concurrent private placement with Sanofi for $50.0 million: 1,532,691 common shares and pre-funded warrants for 1,408,485 shares at IPO price.
- Underwriters granted option to purchase up to 1,544,117 additional shares.
- Estimated net proceeds of $203.8 million from IPO and private placement ($228.0 million if overallotment exercised).
- Pro forma as adjusted cash, cash equivalents and marketable securities of $411.1 million as of June 30, 2026.
- Net loss of $42.6 million for six months ended June 30, 2026; accumulated losses of $93.2 million.
- Cash, cash equivalents and marketable securities of $207.3 million as of June 30, 2026.
- Lead candidates: WIN378 (anti-TSLP, Phase 2/3 in asthma, Phase 2 in COPD) and WIN027 (anti-TSLP/IL-13 bispecific, Phase 1).
- Proceeds to fund WIN378 and WIN027 clinical programs, bispecific IND-enabling studies, and working capital into first half of 2029.
- Series B investors waived $55.0 million second tranche commitment on October 30, 2026.
Financial Impact
Estimated net proceeds of $203.8 million from IPO and concurrent private placement, increasing pro forma as adjusted cash to $411.1 million.
Risk Factors
- Clinical-stage biotech with no approved products or revenue; history of significant losses.
- Dependence on successful clinical development and regulatory approval of WIN378 and WIN027.
- Reliance on third-party manufacturers and licensors in China (Kelun, HBM, Qyuns) with associated geopolitical and supply chain risks.
- Substantial milestone and royalty obligations under license agreements.
- Swiss corporate structure with different shareholder rights and limited U.S. investor protections.
- No prior public market for shares; price volatility expected.
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001193125-26-452536 |
| Document: d111653dex32.htm | 0001193125-26-452536 |
| Document: d111653dex11.htm | 0001193125-26-452536 |
Track record
15 reports on WWB
Filters
- Nov 16, 2026today Press Release Neutral 5/10 Entry $30.04 Now $30.04 +0.00% settles Dec 16
- Nov 13, 20263d ago Press Release Bullish 5/10 Entry $18.35 Now $30.04 +63.71% settles Dec 15
- Nov 13, 20264d ago EFFECT Neutral 6/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 3/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $28.50 Now $30.04 +5.40% settles Dec 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers